Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
The Danish company Novo says U.S.-based Lilly isn’t including the most up-to-date clinical information about its drugs.
The Danish company Novo says U.S.-based Lilly isn’t including the most up-to-date clinical information about its drugs. This story matters for Finance & Markets readers tracking trade. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. Trade-News curates and briefs the finance & markets stories that matter. Our editorial policy →